MWM
PETX

Merriman Wealth Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Merriman Wealth Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$58K – 222
2018
Q3 		$58K Hold
10,000
– – 0.01% 172
2018
Q2 		$43K Buy
+10,000
New +$50.4K 0.01% 164

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Merriman Wealth Management's PETX Position: Q4 2018 in Review

Merriman Wealth Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2018, closing a stake of 10,000 shares — an estimated $58K sold.

Merriman Wealth Management first reported a position in PETX in Q2 2018 and held it in 2 quarters. The position peaked at $58K in Q3 2018. 115 funds tracked by Wall St. Rank hold PETX as of Q4 2018.

  • Merriman Wealth Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Merriman Wealth Management sold 10,000 Aratana Therapeutics, Inc. shares in Q4 2018, an estimated $58K.
  • Merriman Wealth Management first reported a position in Aratana Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • Merriman Wealth Management's Aratana Therapeutics, Inc. position peaked at $58K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2018.

Based on Merriman Wealth Management's 13F filing for Q4 2018, filed 28 Jan 2019.